drugset / Trial / NCT05728684
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.
Timeline
- Start
- 2023-02-28
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM310 | Monoclonal antibody | — | Subcutaneous |